Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Wei

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Cancer Cell|February 10, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Cancer Cell|September 14, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Blood|December 27, 2022
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtypeDevendra Hiwase, Christopher Hahn, Elizabeth Ngoc Hoa Tran, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Cancer Discovery|September 27, 2018
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSean Caenepeel, Sean P Brown, Brian Belmontes, et al.
Genome Research|March 22, 2019
Resolving the full spectrum of human genome variation using Linked-ReadsPatrick Marks, Sarah Garcia, Alvaro Martinez Barrio, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Cancer Cell|February 10, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Internal Medicine Journal|May 28, 2021
COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statementGeorgia McCaughan, Pietro Di Ciaccio, Michelle Ananda-Rajah, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Cancer Cell|September 14, 2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticsNajoua Lalaoui, Kay Hänggi, Gabriela Brumatti, et al.
Blood|December 27, 2022
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtypeDevendra Hiwase, Christopher Hahn, Elizabeth Ngoc Hoa Tran, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Cancer Discovery|September 27, 2018
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSean Caenepeel, Sean P Brown, Brian Belmontes, et al.
Genome Research|March 22, 2019
Resolving the full spectrum of human genome variation using Linked-ReadsPatrick Marks, Sarah Garcia, Alvaro Martinez Barrio, et al.
Pageof 10